Safety, Tolerability, and Pharmacokinetics of HM15275, a Novel GLP-1, GIP, and Glucagon Triple Receptor Agonist—Preliminary Results from a Phase 1 Study

Authors
Category Primary study
ConferenceDiabetes
Year 2025
This article has no abstract
Epistemonikos ID: 4b4d5453605fe9d931f685597b5b6443e5dcdb69
First added on: May 18, 2026